NDA 202439 · Janssen Pharms
Xarelto
Rivaroxaban · Oral
Last checked: Nov 20, 2026Latest source record: Mar 1, 2022 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2011
Nov 4, 2011
Approved uses
5
Original approval plus efficacy supplements
Registered trials
419
129 Phase 3, 75 recruiting
FAERS reports
208,599
174,869 serious, 27,259 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 23, 2021 Supplement 35 · Efficacy LetterLabelReview
- Mar 10, 2020 Supplement 31 · Efficacy LetterLabel
- Oct 11, 2018 Supplement 25 · Efficacy Label
- May 6, 2016 Supplement 17 · Efficacy LabelLetter
- Nov 4, 2011 Original approval · Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval ReviewLabelLetter
4 products under this application
- XARELTO · RIVAROXABAN 20MG · TABLET, ORAL · Prescription
- XARELTO · RIVAROXABAN 10MG · TABLET, ORAL · Prescription
- XARELTO · RIVAROXABAN 2.5MG · TABLET, ORAL · Prescription
- XARELTO · RIVAROXABAN 15MG · TABLET, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Rivaroxaban" as an intervention, any sponsor and status, largest first.
- Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery DiseasePivotal-lookingCompleted
BayerBayer (BAYRY)
NCT01776424 · 27,395 participants · Start Feb 28, 2013 · Primary completion Jul 21, 2017
Drug: Rivaroxaban (Xarelto, BAY59-7939); Rivaroxaban (Xarelto, BAY59-7939) and 5 more · For: Prevention & Control
Sites: Birmingham, Alabama; Mobile, Alabama; Anaheim, California · 565 sites in all
- Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee ReplacementPivotal-lookingCompleted
Dartmouth-Hitchcock Medical CenterAcademic, hospital or other
NCT02810704 · 18,883 participants · Start Dec 2016 · Primary completion Sep 2025
Drug: Enteric Coated Aspirin; Warfarin and 1 more · For: Pulmonary Embolism; Venous Thrombosis
Sites: Scottsdale, Arizona; Little Rock, Arkansas; Los Angeles, California · 32 sites in all
- An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary SyndromePivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00809965 · 15,526 participants · Start Nov 2008 · Primary completion Sep 2011
Drug: Rivaroxaban 2.5 mg; Rivaroxaban 5 mg and 2 more · For: Acute Coronary Syndrome; Myocardial Infarction; Myocardial Ischemia and 1 more
Sites: Birmingham, Alabama; Geneva, Alabama; Mobile, Alabama · 556 sites in all
- An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial FibrillationPivotal-lookingCompleted
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Johnson & Johnson (Janssen) (JNJ)
NCT00403767 · 14,269 participants · Start Dec 2006 · Primary completion Sep 2010
Drug: Rivaroxaban; Warfarin and 2 more · For: Atrial Fibrillation; Stroke; Embolism
Sites: Birmingham, Alabama; Dothan, Alabama; Geneva, Alabama · 932 sites in all
- A Study of Rivaroxaban (JNJ-39039039) on the Venous Thromboembolic Risk in Post-Hospital Discharge PatientsPivotal-lookingCompleted
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT02111564 · 12,024 participants · Start Jan 7, 2014 · Primary completion Mar 6, 2018
Drug: Rivaroxaban, 10 mg; Rivaroxaban, 7.5 mg and 1 more · For: Heart Failure; Respiratory Insufficiency; Stroke Acute and 2 more
Sites: Birmingham, Alabama; Mobile, Alabama; Sheffield, Alabama · 593 sites in all
- The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial FibrillationPivotal-lookingActive, not recruiting
Herlev and Gentofte HospitalAcademic, hospital or other
NCT03129490 · 11,000 participants (planned) · Start Apr 1, 2023 · Primary completion Oct 30, 2027
Drug: Dabigatran Etexilate Oral Capsule; Rivaroxaban Oral Tablet and 2 more · For: Atrial Fibrillation; Atrial Flutter
Sites: Aalborg, Denmark; Aarhus, Denmark; Ballerup Municipality, Denmark · 38 sites in all
- Thromboprophylaxis in Lower Limb ImmobilisationPivotal-lookingRecruiting
Queen Mary University of LondonAcademic, hospital or other
NCT06370273 · 10,044 participants (planned) · Start Nov 12, 2024 · Primary completion Aug 31, 2028
Drug: Rivaroxaban; Apixaban and 4 more · For: Thrombosis; Injury Leg
Sites: Carshalton, United Kingdom; Hull, United Kingdom; London, United Kingdom · 5 sites in all
- Comparing the Safety and Efficacy of Apixaban and RivaroxabanPivotal-lookingRecruiting
VA Office of Research and DevelopmentFederal agency
NCT06953726 · 10,000 participants (planned) · Start Jun 1, 2026 · Primary completion Oct 4, 2032
Drug: Apixaban; Rivaroxaban · For: Atrial Fibrillation
Sites: West Los Angeles, California; Miami, Florida; Boston, Massachusetts · 9 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- gastrointestinal haemorrhage21,673
- off label use8,056
- haemorrhage7,819
- dyspnoea7,421
- epistaxis6,806
- fatigue6,801
- death6,190
- fall6,184
- pulmonary embolism6,046
- drug ineffective6,005
- diarrhoea5,790
- anaemia5,772
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 4 |
| 2008 | 3 |
| 2009 | 52 |
| 2010 | 55 |
| 2011 | 503 |
| 2012 | 3,861 |
| 2013 | 7,368 |
| 2014 | 9,409 |
| 2015 | 27,674 |
| 2016 | 29,714 |
| 2017 | 22,442 |
| 2018 | 21,010 |
| 2019 | 21,502 |
| 2020 | 14,671 |
| 2021 | 10,008 |
| 2022 | 10,492 |
| 2023 | 9,332 |
| 2024 | 8,319 |
| 2025 | 7,035 |
| 2026 | 5,145 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Xarelto (Rivaroxaban)
2024 spending
$6.23B
Beneficiaries
1,321,019
6,660,246 claims
Per beneficiary
$4,718
$17.68 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,701,314,805 |
| 2021 | $5,225,547,772 |
| 2022 | $5,772,682,548 |
| 2023 | $6,309,246,823 |
| 2024 | $6,232,231,840 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism.
Castellucci LA, Chen VM, Kovacs MJ, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Comparative Study
- Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.
Pengo V, Denas G, Zoppellaro G, et al. · Blood 2018 · Clinical Trial, Phase III, Multicenter Study
- Antithrombotic Therapy after Successful Catheter Ablation for Atrial Fibrillation.
Verma A, Birnie DH, Jiang C, et al. · N Engl J Med 2026 · Clinical Trial, Phase IV, Equivalence Trial
- Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
Patel MR, Mahaffey KW, Garg J, et al. · N Engl J Med 2011 · Comparative Study, Multicenter Study
- Rivaroxaban in Peripheral Artery Disease after Revascularization.
Bonaca MP, Bauersachs RM, Anand SS, et al. · N Engl J Med 2020 · Multicenter Study, Randomized Controlled Trial
- Rivaroxaban compared with standard anticoagulants for the treatment of acute venous thromboembolism in children: a randomised, controlled, phase 3 trial.
Male C, Lensing AWA, Palumbo JS, et al. · Lancet Haematol 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Johnson & Johnson (Janssen)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.